Systematic review of the incidence and risk factors of hypertension among HIV-positive individuals

HE Chunyan; XU Xiaohui; HE Na; DING Yingying

doi:10.16462/j.cnki.zhjbkz.2024.06.016

Volume 28 Issue 6

Jun. 2024

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2024 > 28(6): 721-728

HE Chunyan, XU Xiaohui, HE Na, DING Yingying. Systematic review of the incidence and risk factors of hypertension among HIV-positive individuals[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(6): 721-728. doi: 10.16462/j.cnki.zhjbkz.2024.06.016

Citation:

HE Chunyan, XU Xiaohui, HE Na, DING Yingying. Systematic review of the incidence and risk factors of hypertension among HIV-positive individuals[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(6): 721-728. doi: 10.16462/j.cnki.zhjbkz.2024.06.016

Citation:

PDF( 1006 KB)

Systematic review of the incidence and risk factors of hypertension among HIV-positive individuals

doi: 10.16462/j.cnki.zhjbkz.2024.06.016

HE Chunyan^{1, 2},
XU Xiaohui²,
HE Na¹,
DING Yingying^{1
,
,}

1.
School of Public Health, Fudan University, Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, Shanghai 200032, China
2.
Department of HIV/AIDS, Sexually Transmitted Infections, and Leprosy Prevention and Treatment, Shanghai Municipal Center for Disease Control & Prevention, Shanhai 200336, China

Funds:

Shanghai Natural Science Foundation 21ZR1403800

National Key Research and Development Program of China 2022YFC2304901

More Information

Corresponding author: DING Yingying, E-mail: dingyy@fudan.edu.cn
Received Date: 2024-01-05
Rev Recd Date: 2024-05-07

Available Online: 2024-07-13

Publish Date: 2024-06-10

Abstract

Abstract

Objective To systematically review the incidence density and influencing factors of hypertension in HIV positive people in order to explore the potential mechanisms of hypertension in HIV positive individuals. Methods We search literature related to incident hypertension among HIV-positive individuals through CNKI, Wanfang, PubMed, EMbase, Web of Science and Medline, databases and the basic information, incidence density and risk factors were extracted. Results A total of 20 studies were included, comprising 5 from North America, 5 from Africa, 4 from Asia, 2 from Europe, and 4 from multicenter studies. The incidence density of hypertension in HIV-positive individuals ranged from 26.0 to 320.1 per 1 000 person-years. The risk factors of incident hypertension in HIV-positive individuals include traditional risk factors such as age, gender, race, BMI and abdominal obesity, diabetes, kidney disease, dyslipidemia, etc. HIV-specific factors included time of HIV infection, duration of antiviral therapy (ART), and antiviral drugs. Conclusions The incidence density of hypertension is relatively high among HIV-positive individuals, and the geographical variations are particularly pronounced. The contribution of traditional risk factors to incident hypertension among HIV-positive individuals is well established, underscoring the importance of implementing comprehensive strategies and interventions for primary prevention within this population's lifetstyles. However, the role of HIV and ART-related risk factors in hypertension remains unclear, and prospective studies are needed to better elucidate the epidemiology of hypertension in HIV-positive individuals.
- Human immunodeficiency virus positive,
- Hypertension,
- Incidence density

FullText(HTML)

References(41)

References

[1]	Nat Cheza A, Tlou B, Zhou DT. Incidence of non-communicable diseases (NCDs) in HIV patients on ART in a developing country: case of Zimbabwe's Chitungwiza Central Hospital-a retrospective cohort study (2010-2019)[J]. PLoS One, 2021, 16(5): e0252180. DOI: 10.1371/journal.pone.0252180.
[2]	Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: a: d): a multicohort collaboration[J]. Lancet, 2014, 384(9939): 241-248. DOI: 10.1016/S0140-6736(14)60604-8.
[3]	Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study[J]. Lancet Infect Dis, 2015, 15(7): 810-818. DOI: 10.1016/S1473-3099(15)00056-0.
[4]	Chiwandire N, Zungu N, Mabaso M, et al. Trends, prevalence and factors associated with hypertension and diabetes among South African adults living with HIV, 2005-2017[J]. BMC Public Health, 2021, 21(1): 462. DOI: 10.1186/s12889-021-10502-8.
[5]	徐小慧, 何春燕, 何纳, 等. HIV感染者高血压患病率及其影响因素研究近况[J]. 上海预防医学, 2021, 33(12): 1166-1175. DOI: 10.19428/j.cnki.sjpm.2021.20765. Xu XH, He CY, He N, et al. A systematic review of the prevalence and influence factors of hypertension among HIV-infected individuals[J]. Shanghai J Prev Med, 2021, 33(12): 1166-1175. DOI: 10.19428/j.cnki.sjpm.2021.20765.
[6]	Sarfo FS, Norman B, Appiah L, et al. Factors associated with incidence of stroke and heart failure among people living with HIV in Ghana: evaluating vascular event risk while on long-term antiretroviral suppressive therapy (EVERLAST) study[J]. J Clin Hypertens, 2021, 23(6): 1252-1259. DOI: 10.1111/jch.14255.
[7]	Muiru AN, Madden E, Chilingirian A, et al. The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment[J]. HIV Med, 2022, 23(6): 611-619. DOI: 10.1111/hiv.13216.
[8]	Guzman VA, Cham H, Gutierrez J, et al. The longitudinal effects of blood pressure and hypertension on neurocognitive performance in people living with HIV[J]. J Acquir Immune Defic Syndr, 2021, 88(2): 197-205. DOI: 10.1097/QAI.0000000000002740.
[9]	Wong C, Gange SJ, Buchacz K, et al. First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013[J]. Clin Infect Dis, 2017, 64(4): 459-467. DOI: 10.1093/cid/ciw804.
[10]	Sarfo FS, Singh A, Tagge R, et al. Duration of antiretroviral therapy among people living with HIV and incidence of hypertension in Ghana[J]. J Clin Hypertens, 2020, 22(12): 2361-2371. DOI: 10.1111/jch.14088.
[11]	Factor SH, Lo Y, Schoenbaum E, et al. Incident hypertension in older women and men with or at risk for HIV infection[J]. HIV Med, 2013, 14(6): 337-346. DOI: 10.1111/hiv.12010.
[12]	Tripathi A, Jerrell JM, Skelton TN, et al. Incidence of primary hypertension in a population-based cohort of HIV-infected compared with non-HIV-infected persons and the effect of combined antiretroviral therapy[J]. J Am Soc Hypertens, 2015, 9(5): 351-357. DOI: 10.1016/j.jash.2015.01.007.
[13]	Okeke NL, Davy T, Eron JJ, et al. Hypertension among HIV-infected patients in clinical care, 1996-2013[J]. Clin Infect Dis, 2016, 63(2): 242-248. DOI: 10.1093/cid/ciw223.
[14]	Okello S, Kanyesigye M, Muyindike WR, et al. Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda[J]. J Hypertens, 2015, 33(10): 2039-2045. DOI: 10.1097/HJH.0000000000000657.
[15]	Lucas GM, Lau B, Atta MG, et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races[J]. J Infect Dis, 2008, 197: 1548-1557. DOI: 10.1086/587994.
[16]	De Socio GV, Ricci E, Maggi P, et al. Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and hypertension study[J]. J Hypertens, 2017, 35(2): 409-416. DOI: 10.1097/HJH.0000000000001150.
[17]	Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary artery risk development in (young) adults[J]. J Hum Hypertens, 1999, 13(1): 13-21. DOI: 10.1038/sj.jhh.1000740.
[18]	Rodríguez-Arbolí E, Mwamelo K, Kalinjuma AV, et al. Incidence and risk factors for hypertension among HIV patients in rural Tanzania-A prospective cohort study[J]. PLoS One, 2017, 12(3): e0172089. DOI: 10.1371/journal.pone.0172089.
[19]	Freitas P, Carvalho D, Santos AC, et al. Central/peripheral fat mass ratio is associated with increased risk of hypertension in HIV-infected patients[J]. J Clin Hypertens, 2012, 14(9): 593-600. DOI: 10.1111/j.1751-7176.2012.00671.x.
[20]	Xu XH, Chen XX, Lin HJ, et al. General and abdominal obesity and incident hypertension among people living with HIV on antiretroviral therapy[J]. AIDS Care, 2021, 33(12): 1616-1620. DOI: 10.1080/09540121.2020.1852158.
[21]	Krauskopf K, Van Natta ML, Danis RP, et al. Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy[J]. J Int Assoc Provid AIDS Care, 2013, 12(5): 325-333. DOI: 10.1177/2325957413491432.
[22]	Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions[J]. Lancet, 2012, 380(9841): 601-610. DOI: 10.1016/S0140-6736(12)60987-8.
[23]	Manner IW, Baekken M, Oektedalen O, et al. Hypertension and antihypertensive treatment in HIV-infected individuals. A longitudinal cohort study[J]. Blood Press, 2012, 21(5): 311-319. DOI: 10.3109/08037051.2012.680742.
[24]	Cowley AW Jr, Roman RJ. The role of the kidney in hypertension[J]. JAMA, 1996, 275(20): 1581-1589.
[25]	Thiébaut R, El-Sadr WM, Friis-Møller N, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients[J]. Antivir Ther, 2005, 10(7): 811-823. DOI: 10.1177/135965350501000706.
[26]	Hatleberg CI, Ryom L, Monforte AD, et al. Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the data collection on adverse events of anti-HIV drugs (D: a: d) study[J]. HIV Med, 2018, 19(9): 605-618. DOI: 10.1111/hiv.12639.
[27]	Srikanth S, Deedwania P. Management of dyslipidemia in patients with hypertension, diabetes, and metabolic syndrome[J]. Curr Hypertens Rep, 2016, 18(10): 76. DOI: 10.1007/s11906-016-0683-0.
[28]	Brennan AT, Jamieson L, Crowther NJ, et al. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa[J]. PloS one, 2018, 13(10): e0204020. DOI: 10.1371/journal.pone.0204020.
[29]	Batavia AS, Severe P, Lee MH, et al. Blood pressure and mortality in a prospective cohort of HIV-infected adults in Port-au-Prince, Haiti[J]. J Hypertens, 2018, 36(7): 1533-1539. DOI: 10.1097/HJH.0000000000001723.
[30]	Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension[J]. Hypertension, 2011, 57(2): 132-140. DOI: 10.1161/HYPERTENSIONAHA.110.163576.
[31]	Cattelan AM, Trevenzoli M, Sasset L, et al. Indinavir and systemic hypertension[J]. AIDS, 2001, 15(6): 805-807. DOI: 10.1097/00002030-200104130-00021.
[32]	Seaberg EC, Muñoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003[J]. AIDS, 2005, 19(9): 953-960. DOI: 10.1097/01.aids.0000171410.76607.f8.
[33]	Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy[J]. AIDS, 2006, 20(7): 1019-1026. DOI: 10.1097/01.aids.0000222074.45372.00.
[34]	Palacios R, Santos J, García A, et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients[J]. HIV Med, 2006, 7(1): 10-15. DOI: 10.1111/j.1468-1293.2005.00333.x.
[35]	Xu YN, Chen XG, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis[J]. J Am Soc Hypertens, 2017, 11(8): 530-540. DOI: 10.1016/j.jash.2017.06.004.
[36]	Okello S, Asiimwe SB, Kanyesigye M, et al. D-dimer levels and traditional risk factors are associated with incident hypertension among HIV-infected individuals initiating antiretroviral therapy in Uganda[J]. J Acquir Immune Defic Syndr, 2016, 73(4): 396-402. DOI: 10.1097/QAI.0000000000001074.
[37]	Mulugeta H, Afenigus AD, Haile D, et al. Incidence and predictors of hypertension among HIV patients receiving ART at public health facilities, Northwest Ethiopia: a one-year multicenter prospective follow-up study[J]. HIV/AIDS, 2021, 13: 889-901. DOI: 10.2147/HIV.S329838.
[38]	Kim J, Bang JH, Shin JY, et al. Hypertension risk with abacavir use among HIV-infected individuals: a nationwide cohort study[J]. Yonsei Med J, 2018, 59(10): 1245-1252. DOI: 10.3349/ymj.2018.59.10.1245.
[39]	Fan HW, Guo FP, Hsieh E, et al. Incidence of hypertension among persons living with HIV in China: a multicenter cohort study[J]. BMC Public Health, 2020, 20(1): 834. DOI: 10.1186/s12889-020-08586-9.
[40]	Remch M, Franceschini N, Davy-Mendez T, et al. Hypertension burden, treatment, and control among people with HIV at a clinical care center in the Southeastern US, 2014-2019[J]. AIDS Care, 2023, 35(10): 1594-1603. DOI: 10.1080/09540121.2022.2148626.
[41]	Byonanebye DM, Polizzotto MN, Neesgaard B, et al. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium[J]. HIV Med, 2022, 23(8): 895-910. DOI: 10.1111/hiv.13273.